Cost-Effectiveness Analysis of Simvastatin and Atorvastatin in Hypertensive patients with type 2 Diabetes Mellitus Comorbidities at KHZ Musthafa Regional Hospital: from the provider’s perspective

Dheana Ratu Hazlisa; Nur Rahayuningsih; Citra Dewi Salasanti

doi:10.52434/jifb.v17i2.43785

Penulis

Dheana Ratu Hazlisa Universitas Bakti Tunas Husada
Nur Rahayuningsih Universitas Bakti Tunas Husada
Citra Dewi Salasanti Universitas Bakti Tunas Husada

DOI:

https://doi.org/10.52434/jifb.v17i2.43785

Kata Kunci:

atorvastatin, cost-effectiveness analysis, hypertension, simvastatin, type 2 diabetes mellitus

Abstrak

Hypertension with comorbid type 2 diabetes mellitus is a chronic condition strongly associated with an increased risk of cardiovascular complications, such as coronary heart disease, stroke, and vascular damage. This condition requires pharmacological therapy that is not only clinically effective but also cost-effective in terms of healthcare services. In clinical practice, statins such as simvastatin and atorvastatin are frequently used as lipid-lowering therapy to help reduce the risk of cardiovascular complications in patients with metabolic diseases. However, differences in treatment costs and clinical outcomes between these two medications make pharmacoeconomic evaluation crucial in determining the most cost-effective therapeutic option. This study aims to analyze the cost-effectiveness of simvastatin and atorvastatin use in hypertensive patients with type 2 diabetes mellitus comorbidity from the perspective of healthcare providers at KHZ Musthafa Regional General Hospital, Tasikmalaya. This study employed a retrospective cross-sectional design based on medical records and patient billing data from January 2024 to December 2025. Using purposive sampling, 57 patients who met the inclusion criteria were included in the study. Cost-effectiveness analysis was performed by calculating direct medical costs, therapeutic effectiveness based on the average length of hospital stay (LOS), the Average Cost-Effectiveness Ratio (ACER), and the Incremental Cost-Effectiveness Ratio (ICER). The results showed that the group of patients receiving simvastatin had lower direct medical costs, namely Rp4,269,569, compared to the atorvastatin group at Rp5,902,031. In addition, the simvastatin group also showed a shorter average length of stay, namely 3.8 days, while the atorvastatin group reached 4.7 days. The ICER for simvastatin was recorded at Rp1,123,570 per day, which is lower than that of atorvastatin at Rp1,255,751 per day. Based on these results, simvastatin is considered more cost-effective than atorvastatin in hypertensive patients with type 2 diabetes mellitus, making it a potentially more efficient therapeutic option for hospitals.

Referensi

1. Damayanti VW, Yonata A, Kurniawaty E. Hipertensi pada diabetes melitus: patofisiologi dan faktor risiko. Medula. 2023;14(1):1253–7.

2. Liao C Te, Toh HS, Sun L, Yang CT, Hu A, Wei D, et al. Cost-effectiveness of intensive vs standard blood pressure control among older patients with hypertension. JAMA Netw Open. 2023;6(2):1–13.

3. Supadmi W, Sary MI, Gailea A, Monica L, Saputri GZ, Hastuti D. Hubungan tingkat pengetahuan dan kepatuhan pasien hipertensi di apotek di Yogyakarta. Maj Farm. 2024;20(2):154–60.

4. Taheri A, Khezri R, Dehghan A, Rezaeian M, Aune D, Rezaei F. Hypertension among persons with type 2 diabetes and its related demographic, socioeconomic and lifestyle factors in the Fasa cohort study. Sci Rep. 2024;14(1):1–9.

5. McEvoy JW, McCarthy CP, Bruno RM, Brouwers S, Canavan MD, Ceconi C. 2024 ESC guidelines for the management of elevated blood pressure and hypertension: developed by the task force on the management of elevated blood pressure and hypertension of the European Society of Cardiology (ESC) and endorsed by the European Society of Endocrinology (ESE) and the European Stroke Organisation (ESO). Eur Heart J. 2024 Oct;45(38):3912–4018.

6. Yoo J, Jeon J, Baek M, Song SO, Kim J. Impact of statin treatment on cardiovascular risk in patients with type 1 diabetes: a population-based cohort study. J Transl Med. 2023;21(1):1–11.

7. Elshafeey A. Therapeutic management of LDL-C: efficacy and economic impact assessment. J Cardiovasc Dev Dis. 2025;12(5):1–21.

8. Latif WD, Aswad M, Bahar MA. Perbandingan efektivitas klinik simvastatin dan atorvastatin terhadap profil lipid darah: studi kasus di Rumah Sakit Universitas Hasanuddin. J Sains Farm Klin. 2022;9(1):34–41.

9. Agustin ED, Dewi LVI, Hanifah IR. Analisis efektivitas biaya pengobatan golongan statin dalam manajemen penyakit jantung koroner di RSUD Kota Madiun 2021/2022. J Mandala Pharmacon Indones. 2023;9(2):282–90.

10. Farnier M, Portal JJ, Maigret P. Efficacy of atorvastatin compared with simvastatin in patients with hypercholesterolemia. J Cardiovasc Pharmacol Ther. 2000;5(1):27–32.

11. Mihaylova B, Wu R, Zhou J, Williams C, Schlackow I, Emberson J, et al. Assessing long-term effectiveness and cost-effectiveness of statin therapy in the UK: a modelling study using individual participant data sets. Health Technol Assess (Rockv). 2024;28(79):1–134.

12. Khan S, Huda B, Bhurka F, Patnaik R, Banerjee Y. Molecular and immunomodulatory mechanisms of statins in inflammation and cancer therapeutics with emphasis on the NF-κB, NLRP3 inflammasome, and cytokine regulatory axes. Int J Mol Sci. 2025;26(17):1–107.

13. Azizah SA, Novrianti I. Pharmacotherapy of diabetic mellitus: a review. J Pharm Sci. 2022;5(2):80–91.

14. Kriswiastiny R, Hidayat NA, Mustofa FL, Hermawan D. Hubungan lama menderita diabetes melitus dan kadar gula darah dengan kadar kolesterol total pada pasien diabetes melitus tipe 2 di Rumah Sakit Pertamina Bintang Amin Husada Bandar Lampung tahun 2021. Medula. 2022;12(3):486–94.

15. Ma KJ, Hsu YC, Pan WW, Chou MH, Chung W, Wang JY. Effects of emergency department length of stay on inpatient utilization and mortality. Health Econ Rev. 2025;15(1):1–8.

16. Dewi PEN, Thavorncharoensap M, Rahajeng B. Cost–utility analysis of using high-intensity statin among post-hospitalized acute coronary syndrome patients. Egypt Hear J. 2024;76(1):1–12.

17. Gandjour A. Health-economic evaluation of statins versus lifestyle changes for cardiovascular disease prevention. PLoS One. 2025;20(9):1–13.

18. Zhou W, Liang Z, Lou X. The combination use of inclisiran and statins versus statins alone in the treatment of dyslipidemia in mainland China : a cost-effectiveness analysis. 2024;(February):1–10.

19. Moradi S, Najafpour Z, Cheraghian B, Keliddar I, Mombeyni R. The extra length of stay, costs, and mortality associated with healthcare-associated infections: a case-control study. Heal Sci Reports. 2024;7(11):1–8.

20. Abdullah, Asim Z. Cost effectiveness of mono, dual, and triple therapy of antihypertensive drugs: a retrospective cohort study. Cost Eff Resour Alloc. 2025;23(1):1–9.

21. Bilcke J, Beutels P. Generating, presenting, and interpreting cost-effectiveness results in the context of uncertainty: a tutorial for deeper knowledge and better practice. Med Decis Mak. 2022;42(4):421–35.

22. Putri RFP, Wibowo W, Sawu SD. Perbandingan efektivitas penggunaan atorvastatin dan simvastatin pada pasien penyakit jantung koroner yang dirawat inap di Rumah Sakit “X” Kota Batu. JFM (Jurnal Farm Malahayati). 2025;8(1):23–34.

23. Chow R, Simone CB, Prsic EH, Shin HJ. Cost-effectiveness analysis of statins for the treatment of hospitalized COVID-19 patients. Ann Palliat Med. 2022;11(7):2285–90.